Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Prakash Chelladurai has a total of 209 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data from The HDAC2-SP1 Axis Orchestrates Protumor Macrophage Polarization

    by Xiang Zheng, Poonam Sarode, Andreas Weigert, Kati Turkowski, Prakash Chelladurai, Stefan Günther, Carsten Kuenne, Hauke Winter, Albrecht Stenzinger, Simone Reu, et al.

    Supplementary Data with figires_tables

  • SUN1 Accumulation mediates nuclear alteration, a novel hallmark driving Pulmonary hypertension.

    by Samuel Olapoju, Sarah Eve-Lemay, Prakash Chelladurai, Tara Procida, Anoop Cherian, Dmitry A Goncharov, Golnaz Hesami, Stefan Gunther, Marek Bartkuhn, Werner Seeger, et al.

  • Open Access

    Transcriptional changes of the extracellular matrix in chronic thromboembolic pulmonary hypertension govern right ventricle remodeling and recovery

    by Leili Jafari, Christoph B Wiedenroth, Steffen D Kriechbaum, Dimitri Grün, Prakash Chelladurai, Stefan Guenther, Carsten Kuenne, Alicia M Späth, Anoop V Cherian, Christian Troidl, et al.

    Chronic thromboembolic pulmonary hypertension (CTEPH) leads to progressive right ventricular (RV) dysfunction. Pulmonary endarterectomy (PEA) is an established treatment for these patients; however, the molecular mechanisms underlying RV remodeling and recovery remain poorly understood. Here we show that RNA sequencing and histological analysis of RV free wall and septal biopsies from patients with CTEPH reveal extracellular matrix enrichment and cytoskeletal remodeling before PEA. These changes were consistent across an exploratory and confirmatory cohort. Post-PEA samples showed reversal of both histological and transcriptional abnormalities. Key signaling molecules—ANKRD1, IL7R and SERPINE1—were implicated in fibrotic and proliferative pathways, as confirmed in human tissues and experimental models. Our findings identify a reversible gene expression and structural remodeling signature in the RV, linking hemodynamic unloading with molecular recovery. These insights suggest potential therapeutic targets to modulate maladaptive RV remodeling in CTEPH and improve outcomes beyond surgical intervention.


  • Actin Cytoskeletal Remodeling Mediates SUN1/ARPC5 Protein Accumulation to Drive Nuclear Architectural Alteration; A Novel Signaling Axis in Pulmonary Hypertension

    by S. Olapoju, P. Chelladurai, A. Cherian, S.-E. Lemay, D. Goncharov, G. Hesami, S. Gunther, M. Bartkuhn, R. Savai, W. Seeger, et al.

    Rationale Pulmonary hypertension (PH) is a deadly disease characterized by hyperproliferation and reduced apoptotic ability of pulmonary vascular cells. Due to limited treatment options, unravelling novel drug able signaling axis to be modulated as a therapeutic strategy is of utmost interest.The nuclear cellular compartment is a key organelle driving numerous biological processes, it is therefore important that the nuclear structural integrity is maintained to ensure its optimal functioning. Unfortunately, the nuclear structural integrity could be compromised or altered as a result of cellular stress, or mechanosensing. This has been a concept in various pathological conditions but not yet elucidated in the context of pulmonary hypertension. Thus, the aim of this study is to unravel how actin cytoskeleton can alter nuclear structure, and drive the phenotype observed in pulmonary hypertension towards novel therapeutic approach. Methods Using confocal microscopy, we profiled possible alterations in cytoskeleton and nuclear structures in IPAH patients, Hypoxic PCLS and Jasplakinolide-stimulated pulmonary arterial smooth muscle cells. In addition, we employed siRNA mediated knockdown strategy, pharmacological inhibition, gene and protein expression profiling (western blotting, immunofluorescence and qPCR) and bulk RNA-sequencing to identify key drivers and pathways involved the observed phenotype.Also, chromatin accessibility assay was used to investigate the enrichment of the signaling molecule of the predicted pathway upon actin disruption and our patients’ cohort. Finally, we studied the regulation of SUN1/ARPC5 and the effect of XMU-MP-1 (Hippo inhibitor) using Monocrotaline-induced PH rat model. Result: Our results show that Jasplakinolide induced the accumulation of SUN1 protein which correlates with increased actin related protein complex 5 (ARPC5), Loss of nuclear circularity, volume and nuclear shrinking. This same phenotype was observed in IPAH, Hypoxic PCLS and MCT-induced PH when compared with respective control groups.RNA-seq and chromatin accessibility assay inferred dysregulation of Hippo signaling and altered enrichment of Hippo molecules upon actin maneuver. Moreover, siRNA KD of SUN1/ARPC5 axis ameliorated the phenotype observed upon actin polymerization, IPAH phenotype and dysregulates hippo pathway.In vivo data using the Hippo signaling inhibitor (XMU-MP-1) attenuated PH-like phenotype, ablated the SUN1/ARPC5 axis and reduced hemodynamic alterations upon treatment.Interestingly, MCT-rats treated with XMU-MP-1 showed reduced expression of epigenetic players PCAF, and TBP upon treatment which correlates with reduced expression of key PAH signature genes. Conclusion: our data suggest actin mediated nuclear architectural alteration as a key signature driving PH and can be modulated via ARPC5/SUN1/Hippo signaling axis. Thus, a potential therapeutic option in PH.

  • Open Access

    LOSS OF ROR2 TYROSINE KINASE RECEPTOR IS ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION IN PAH VIA INAPPROPRIATE INTEGRIN β1 ACTIVATION

    by Ankita Mitra, Ananya Chakraborty, Brian Zhong, Lyong Heo, Stuti Agarwal, Amanda Pacheco, Natasha Auer, Alexander Dunn, Prakash Chelladurai, Ananya Jain, et al.

    Rationale Endothelial dysfunction is a key feature of pulmonary arterial hypertension (PAH). We previously identified Wnt7a, a ligand of the Wnt planar cell polarity (PCP) pathway, as essential for pulmonary angiogenesis, with its loss linked to PAH. Given the importance of Wnt/PCP to lung endothelial function and angiogenesis, our goal is to elucidate how Wnt/PCP regulates angiogenic responses in pulmonary microvascular endothelial cells (PMVECs). ROR2, a tyrosine kinase receptor specific to Wnt/PCP, is crucial for cardiovascular development, but its role in PAH is unclear. We hypothesized that ROR2 supports endothelial homeostasis, and its loss would impair angiogenesis, contributing to PAH. Methods Endothelial-specific ROR2 knockout (ROR2 ECKO) and wild-type (WT) mice were studied under normoxia and chronic hypoxia using echocardiography, hemodynamics, and lung morphometry. PMVECs from healthy and PAH lungs were transfected with ROR2 siRNA/constructs for functional and molecular studies. Focal adhesion (FA) activation and force generation were assessed via FRET-based methods. Bulk and single-cell transcriptomic analyses were performed on siROR2 PMVECs and ROR2 ECKO lungs. Results ROR2 ECKO mice exhibited worsened pulmonary hypertension, right ventricular remodeling, microvascular loss, and muscularization in hypoxia. Single-cell RNA sequencing of lung endothelial cells showed dysregulation of pathways involved in barrier formation and angiogenesis. Evans blue dye extravasation confirmed reduced endothelial barrier integrity in ROR2 ECKO mice. ROR2-deficient PAH PMVECs displayed increased adhesion, permeability, and FA numbers, with reduced VE-cadherin at cell junctions. Confocal imaging revealed ROR2 localization in FAs, interacting with integrin β1 (ITGB1). FRET analysis showed that ITGB1 remained in an active, adhesion-promoting state in ROR2-deficient cells. Restoring ROR2 in PAH PMVECs normalized adhesion, barrier function, and FA abundance. Transcriptomic analysis identified Rab12 as a key mediator of ROR2-ITGB1 crosstalk, with Rab12 knockdown mimicking ROR2 deficiency in PMVECs. Conclusions ROR2 regulates pulmonary angiogenesis by maintaining endothelial barrier integrity and facilitating integrin recycling. Restoring ROR2 signaling could be a potential therapeutic approach for PAH.


  • ATP citrate lyase drives vascular remodeling in systemic and pulmonary vascular diseases through metabolic and epigenetic changes

    by Yann Grobs, Charlotte Romanet, Sarah-Eve Lemay, Alice Bourgeois, Pierre Voisine, Charlie Theberge, Melanie Sauvaget, Sandra Breuils-Bonnet, Sandra Martineau, Reem El Kabbout, et al.

    ATP citrate lyase (ACLY), a crucial enzyme in de novo lipid synthesis and histone acetylation, plays a key role in regulating vascular smooth muscle cell (VSMC) proliferation and survival. We found that human coronary and pulmonary artery tissues had up-regulated ACLY expression during vascular remodeling in coronary artery disease and pulmonary arterial hypertension. Pharmacological and genetic inhibition of ACLY in human primary cultured VSMCs isolated from the coronary arteries of patients with coronary artery diseases and from the distal pulmonary arteries of patients with pulmonary arterial hypertension resulted in reduced cellular proliferation and migration and increased susceptibility to apoptosis. These cellular changes were linked to diminished glycolysis, reduced lipid synthesis, impairment in general control nonrepressed protein 5 (GCN5)–dependent histone acetylation and suppression of the transcription factor FOXM1. In vivo studies using a pharmacological inhibitor and VSMC-specific Acly knockout mice showed that ACLY inhibition alleviated vascular remodeling. ACLY inhibition alleviated remodeling in carotid injury and ligation models in rodents and attenuated pulmonary arterial hypertension in Sugen/hypoxia rat and mouse models. Moreover, ACLY inhibition showed improvements in vascular remodeling in human ex vivo models, which included cultured human coronary artery and saphenous vein rings as well as precision-cut lung slices. Our results propose ACLY as a novel therapeutic target for treating complex vascular diseases, offering promising avenues for future clinical intervention.


  • Open Access

    Data from The HDAC2-SP1 axis orchestrates pro-tumor macrophage polarization

    by Xiang Zheng, Poonam Sarode, Andreas Weigert, Kati Turkowski, Prakash Chelladurai, Stefan Günther, Carsten Kuenne, Hauke Winter, Albrecht Stenzinger, Simone Reu, et al.

    Tumor-associated macrophages (TAMs), including anti-tumor M1-like TAMs and pro-tumor M2-like TAMs, are transcriptionally dynamic innate immune cells with diverse roles in lung cancer development. Epigenetic regulators are key in controlling macrophage fate in the heterogeneous tumor microenvironment. Here, we demonstrate that the spatial proximity of HDAC2–overexpressing M2-like TAMs to tumor cells significantly correlates with poor overall survival of lung cancer patients. Suppression of HDAC2 in TAMs altered macrophage phenotype, migration, and signaling pathways related to interleukins, chemokines, cytokines, and T cell activation. In co-culture systems of TAMs and cancer cells, suppressing HDAC2 in TAMs resulted in reduced proliferation and migration, increased apoptosis of cancer cell lines and primary lung cancer cells, and attenuated endothelial cell tube formation. HDAC2 regulated the M2-like TAM phenotype via acetylation of histone H3 and transcription factor SP1. Myeloid cell–specific deletion of Hdac2 and pharmacological inhibition of class I HDACs in four different murine lung cancer models induced the switch from M2-like to M1-like TAMs, altered infiltration of CD4+ and CD8+ T cells, and reduced tumor growth and angiogenesis. TAM-specific HDAC2 expression may provide a biomarker for lung cancer stratification and a target for developing improved therapeutic approaches.

  • Open Access

    Supplementary Data from The HDAC2-SP1 axis orchestrates pro-tumor macrophage polarization

    by Xiang Zheng, Poonam Sarode, Andreas Weigert, Kati Turkowski, Prakash Chelladurai, Stefan Günther, Carsten Kuenne, Hauke Winter, Albrecht Stenzinger, Simone Reu, et al.

    Supplementary Data with figires_tables

  • Open Access

    Supplementary Data from The HDAC2-SP1 axis orchestrates pro-tumor macrophage polarization

    by Xiang Zheng, Poonam Sarode, Andreas Weigert, Kati Turkowski, Prakash Chelladurai, Stefan Günther, Carsten Kuenne, Hauke Winter, Albrecht Stenzinger, Simone Reu, et al.

    Supplementary Data with figires_tables

  • Restoration of Foxp3+ Regulatory T Cells by HDAC-Dependent Epigenetic Modulation Plays a Pivotal Role in Resolving Pulmonary Arterial Hypertension Pathology

    by Chien-Nien Chen, Nabil Hajji, Fu-Chiang Yeh, Sunniyat Rahman, Souad Ali, John Wharton, Nicoleta Baxan, Lin Zhao, Chong-Yang Xie, Yi-Guan Chen, et al.

    Rationale: Immune dysregulation is a common feature of pulmonary arterial hypertension (PAH). Histone deacetylase (HDAC)-dependent transcriptional reprogramming epigenetically modulates immune homeostasis and is a novel disease-oriented approach in modern times. Objectives: To identify a novel functional link between HDAC and regulatory T cells (Tregs) in PAH, aiming to establish disease-modified biomarkers and therapeutic targets. Methods: Peripheral blood mononuclear cells were isolated from patients with idiopathic PAH (IPAH) and rodent models of pulmonary hypertension (PH): monocrotaline rats, Sugen5416-hypoxia rats, and Treg-depleted mice. HDAC inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) was used to examine the immune modulatory effects in vivo, ex vivo, and in vitro. Measurements and Main Results: Increased HDAC expression was associated with reduced Foxp3+ Tregs and increased PD-1 (programmed cell death-1) signaling in peripheral blood mononuclear cells from patients with IPAH. SAHA differentially modified a cluster of epigenetic-sensitive genes and induced Foxp3+ Treg conversion in IPAH T cells. Rodent models recapitulated these epigenetic aberrations and T-cell dysfunction. SAHA attenuated PH phenotypes and restored FOXP3 transcription and Tregs in PH rats; interestingly, the effects were more profound in female rats. Selective depletion of CD25+ Tregs in Sugen5416-hypoxia mice neutralized the effects of SAHA. Furthermore, SAHA inhibited endothelial cytokine/chemokine release upon stimulation and subsequent immune chemotaxis. Conclusions: Our results indicated HDAC aberration was associated with Foxp3+ Treg deficiency and demonstrated an epigenetic-mediated mechanism underlying immune dysfunction in PAH. Restoration of Foxp3+ Tregs by HDAC inhibitors is a promising approach to resolve pulmonary vascular pathology, highlighting the potential benefit of developing epigenetic therapies for PAH.